In-Vitro and In-Vivo Anti-Adipogenecity Activity of Two Plants using Rat Models
Abstract
Keywords
Full Text:
PDFReferences
Assmann, G. (1979) Lipiddiagnostikheute. page 29ff.in Greten. H., et al lipoproteine and Herzinfarkt. Witzstrock. Verlag, Baden-Baden/W. Germany
Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–81.
Ginsberg HN, Goldberg IJ. Disorders of lipoprotein metabolism. In: Braunwald E, Fauci AS, Kasper DL, et al, Internal Medicine. 15th ed. New York, NY: McGraw-Hill Inc; 2001:2245–57
Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med. 2002;162:1568–76.
Guyton AC, Hall JE. Lipid metabolism. In: Textbook of MedicalPhysiology.10thed.Philadelphia,PA:WBSaunders Company;2000:781-90
Henry, J.B., Clinical Diagnosis& management by Laboratory methods, 18th ed., W.B. Saunders, Philadelphia,1991,p.204-211.
J.P. Jani, S. Specht, N. Stemmler, K. Blanock, S.V. Singh, V. Gupta, A. Katoh, Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis, Invasion Metastasis 13 (1993) 314–324.
Lopes-Virella MF, stone p, Ellis S, Colwell JA. Cholesterol determination in HDL separated by three different methods. Clin Chem1977; 23. 882-4
McKenney JM. Dyslipidemias. In: Koda-Kimble MA, Young LY, Kradjan WA, et al, eds. Applied Therapeutics: The Clinical Use of Drugs. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:chap 11
National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, MD: National Institutes of Health; May2001.
R. Hampton, D. Dimster-Denk, J. Rine, The biology of HMG-CoA reductase: the pros of contra-regulation, Trends Biochem. Sci. 21 (1996) 140–145
Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease; the Scandinavian Simvastain survival study (45) Lancet 1994;244;1383-9
Rifai N, Bachorik PS, Albers JJ. Lipids, lipoproteins & Apo-lipoproteins. In Burtis CA, Ashood ER, editors. Tiez Textbook of Clincal Chemistry.3rded. Philadelphia; WB Saunders, company;1999. p. 809-61
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med.1999;341:410–8.
Sack FM, Pfeffer MA, Moye LA, Rouleau Jl, Ruthertford JC, cole TG, et al, The effect of pravasatin on coronary events after MI in patient with average cholesterol levels. New England journal of Medicine 1996;335;1001-9
The lipid Study group, prevention of cardiovascular events and death with paravastain in patients with coronary heart disease and a broad range of initial cholesterol levels. New England journal of medicine 1998; 339; 1349-57
The Long-Term Intervention with Pravastatin in Ischaemic Disease(LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339: 1349–57.
M, Arumugam; P, Vijayan; C, Raghu; G, Ashok; SA, Dhanaraj; and CT, Kumarappan (2008) "Anti-Adipogenic Activity of Capsicum annum (Solanaceae) in 3T3 L1," Journal of Complementary and Integrative Medicine: Vol. 5: Iss. 1, Article 28.)
DOI: https://doi.org/10.37628/ijaba.v6i1.578
Refbacks
- There are currently no refbacks.